Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05ARP
|
|||
| Former ID |
DAP000645
|
|||
| Drug Name |
Ganciclovir
|
|||
| Synonyms |
ganciclovir; 82410-32-0; Gancyclovir; Cytovene; Vitrasert; Hydroxyacyclovir; Ganciclovirum; Zirgan; RS-21592; Cymevene; HHEMG; Biolf 62; BW-759U; Ganciclovirum [Latin]; 2'-NDG; 2-Amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-1H-purin-6(9H)-one; BW 759U; BIOLF-62; 2'-Nor-2'-deoxyguanosine; 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine; BW-B 759U; UNII-P9G3CKZ4P5; DRG-0018; BW 759; 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one; CCRIS 9212; GA2; Cytovene-IV; HSDB 6512
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Virus infection [ICD-11: 1A24-1D9Z] | Approved | [1] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Company |
Bausch & Lomb Pharmaceuticals, Inc.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H13N5O4
|
|||
| Canonical SMILES |
C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N
|
|||
| InChI |
1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)
|
|||
| InChIKey |
IRSCQMHQWWYFCW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 82410-32-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
617697, 866342, 3720872, 5006228, 7298558, 7840003, 7847399, 7887702, 7979369, 8139883, 10321977, 11111224, 11111225, 11466867, 11467987, 11486454, 12013652, 14749970, 14798783, 16217245, 17405102, 23929519, 24278453, 25622077, 26758755, 29222588, 46507294, 47216865, 47515408, 47589082, 48185084, 48185085, 48334596, 48404464, 48404465, 49681203, 49698657, 49974979, 50106328, 50106329, 50113251, 53777645, 53800918, 56312143, 56312588, 56424026, 57321811, 76491727, 81041223, 85231063
|
|||
| ChEBI ID |
CHEBI:465284
|
|||
| ADReCS Drug ID | BADD_D01003 ; BADD_D01004 | |||
| SuperDrug ATC ID |
J05AB06; S01AD09
|
|||
| SuperDrug CAS ID |
cas=082410320
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Herpes simplex virus DNA polymerase UL30 (HSV UL30) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 2 | Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2009 Feb;30(2):77-81. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.